Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
02 Abril 2024 - 9:30AM
Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a
clinical-stage rare disease biopharmaceutical company developing
novel therapeutics for the treatment of pathologic mineralization
and intimal proliferation, today announced that Doug Treco, Ph.D.,
the company’s chief executive officer and chairman of the board,
will participate in a fireside chat at the 23rd Annual Needham
Virtual Healthcare Conference on Tuesday, April 9, 2024 from
10:15-10:55 a.m. ET.
A live webcast of the fireside chat can be
accessed from the Investor Relations section of Inozyme’s
website under events, where a replay of the event will also be
available for a limited time.
About Inozyme Pharma
Inozyme Pharma, Inc. is a clinical-stage rare
disease biopharmaceutical company developing novel therapeutics for
the treatment of diseases impacting the vasculature, soft tissue,
and skeleton. Inozyme is developing INZ-701, an enzyme replacement
therapy, to address pathologic mineralization and intimal
proliferation, which can drive morbidity and mortality in these
severe diseases. INZ-701 is currently in clinical development for
the treatment of ENPP1 Deficiency, ABCC6 Deficiency and
calciphylaxis.
For more information, please
visit https://www.inozyme.com/ or follow Inozyme
on LinkedIn, X (formerly Twitter), and Facebook.
Contacts
Investors:Inozyme PharmaStefan Riley, Senior Director of IR and
Corporate Communications(857) 330-8871stefan.riley@inozyme.com
Media: SmithSolve Matt Pera(973)
886-9150matt.pera@smithsolve.com
Inozyme Pharma (NASDAQ:INZY)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Inozyme Pharma (NASDAQ:INZY)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024